We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIOHIT Healthcare OY

Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App




Finnish Gastric Cancer Biomarker Tests to Be used in Large Chinese Screening Study

By LabMedica International staff writers
Posted on 11 Aug 2015
A panel of tests produced by a Finnish biomedical company that assess gastric cancer risk will be used in a large screening study of asymptomatic persons in China.

The Biohit Oyj (Helsinki, Finland) GastroPanel is a set of four ELISA kits that diagnose Helicobacter pylori infection and atrophic gastritis by determining levels of the biomarkers pepsinogen I (PGI), pepsinogen II (PGII), gastrin-17 (G-17), and H. More...
pylori antibodies. The tests are noninvasive and performed upon small blood samples.

The gastric cancer risk screening study was organized by the China Health Promotion Foundation, a public organization managed by the Chinese Ministry of Health. Testing of approximately 500,000 40–80-year-old asymptomatic persons with GastroPanel assays will be conducted at fifty to one hundred primary healthcare centers across China. Collection of samples began in the summer of 2015, and data collection and analysis, including evaluation, are planned to be finalized by the end of 2016.

Semi Korpela, CEO of Biohit Oyj, said, "This is an outstanding opening for GastroPanel biomarkers in the screening of asymptomatic subjects to disclose the risk groups for gastric cancer and vitamin B12 malabsorption among other things. Gastric cancer is the leading cause of cancer related mortality in China. The use of the very informative GastroPanel for the screening of gastric cancer risk offers the possibility for the prevention and early detection of stomach cancers. Based on correct diagnosis, screening reduces sick leaves and loss of labor input, as well as self-medication with its associated risks. Early detection of risk conditions for gastric cancer and vitamin and mineral deficiencies saves healthcare costs and human suffering as well."

Related Links:

Biohit Oyj



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
New
Silver Member
Urine Test Strips
LabStrip U12 mALB/CREA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The study identified a distinct immune signature associated with treatment-resistant myasthenia gravis (Dodd, Katherine C. et al., Med (2026). DOI: 10.1016/j.medj.2025.100987)

Immune Signature Identified in Treatment-Resistant Myasthenia Gravis

Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.